Literature DB >> 12394755

Outcome of endoscopic treatment for vesicoureteral reflux in children using polydimethylsiloxane.

Adel A Al-Hunayan1, Elijah O Kehinde, Mamdouh A Elsalam, Rola S Al-Mukhtar.   

Abstract

PURPOSE: We reviewed the outcome of subureteral injection of polydimethylsiloxane as a bulking agent for endoscopic treatment for vesicoureteral reflux in patients younger than 12 years.
MATERIALS AND METHODS: A total of 40 children (59 ureters) with primary grades II to IV vesicoureteral reflux were treated with a single subureteral injection from 1997 to 2001 and followed an average of 26 months (range 4 to 45). Results in 38 patients (55 ureteral units) were available for review. Each child underwent preoperative voiding cystourethrography, renal ultrasound, dimercapto-succinic acid scan and urine culture. Treatment was done on an outpatient basis. With the patient general anesthesia polydimethylsiloxane implant was injected transurethrally below the ureteral opening of the affected renal unit. Renal ultrasound at 1 week and voiding cystourethrography at 2 months were done to rule out obstruction at the injection site and/or persistent reflux, respectively. Cure was defined as absent vesicoureteral reflux on voiding cystourethrography 2 months after injection.
RESULTS: After a single injection polydimethylsiloxane cured vesicoureteral reflux in 45 ureteral units (81.8%), while in 5 (9.1%) the condition was improved. The remaining 5 ureteral units (9.1%) showed no change in reflux grade. In 1 patient (1.9%) with unilateral grade IV vesicoureteral reflux contralateral reflux developed. None of the cured patients had recurrent reflux during followup. In 1 patient ureteral obstruction was successfully treated with ureteral reimplantation.
CONCLUSIONS: Endoscopic subureteral injection of polydimethylsiloxane implant in children with primary grades II to IV vesicoureteral reflux appears to be an effective, safe and minimally invasive technique.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394755     DOI: 10.1097/01.ju.0000034704.56305.ef

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Endoscopic subureteral injection treatment with calcium hydroxylapatite in primary vesicoureteral reflux.

Authors:  Bilal Eryildirim; Fatih Tarhan; Uğur Kuyumcuoğlu; Erkan Erbay; Gökhan Faydaci
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

2.  Histological response to injected dextranomer-based implant in a rat model.

Authors:  Murat Alkan; Arbay O Ciftci; Beril Talim; Mehmet E Senocak; Melda Caglar; Nebil Buyukpamukcu
Journal:  Pediatr Surg Int       Date:  2006-10-17       Impact factor: 1.827

3.  Endoscopic Subureteral Injection for the Treatment of Vesicoureteral Reflux in Children: Polydimethylsiloxane (Macroplastique(R)) versus Dextranomer/Hyaluronic Acid Copolymer (Deflux(R)).

Authors:  Young Dae Bae; Min Gu Park; Mi Mi Oh; Du Geon Moon
Journal:  Korean J Urol       Date:  2010-02-18

4.  Combination of calcium hydroxyapatite and autologous blood for endoscopic treatment of vesicoureteral reflux in children.

Authors:  Roozbeh Tanhaeivash; Abdol-Mohammad Kajbafzadeh; Atefeh Zeinoddini; Neda Khalili; Mona Vahidi Rad; Reza Heidari
Journal:  Int Urol Nephrol       Date:  2014-02-20       Impact factor: 2.370

5.  Macroplastique and Botox are superior to Macroplastique alone in the management of neurogenic vesicoureteric reflux in spinal cord injury population with presumed healthy bladders.

Authors:  Vasileios I Sakalis; Rachel Oliver; Peter J Guy; Melissa C Davies
Journal:  J Spinal Cord Med       Date:  2018-02-07       Impact factor: 1.985

6.  Postoperative ureteral obstruction after endoscopic treatment for vesicoureteral reflux.

Authors:  Jae Min Chung; Chang Soo Park; Sang Don Lee
Journal:  Korean J Urol       Date:  2015-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.